"Analysis.group","Analysis.number","Analysis.name","Subgroup","Subgroup.number","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","Bias.arising.from.the.randomization.process.judgement","Bias.arising.from.the.randomization.process.support","Bias.due.to.deviations.from.intended.interventions.judgement","Bias.due.to.deviations.from.intended.interventions.support","Bias.due.to.missing.outcome.data.judgement","Bias.due.to.missing.outcome.data.support","Bias.in.measurement.of.the.outcome.judgement","Bias.in.measurement.of.the.outcome.support","Bias.in.selection.of.the.reported.result.judgement","Bias.in.selection.of.the.reported.result.support","Overall.bias.judgement","Overall.bias.support","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
2,1,"Number of participants with at least one SAE","",NA,"SUBGROUP_AND_OVERALL","NCT04115488 (Antelope)",NA,0,0,0,0,2,103,0,0,3,131,0,0,100,0.847896,0.144356,4.980261,NA,"Some concerns","<p>""Patients were randomized dynamically using Medidata Randomization and Trial Supply Management integrated with electronic data capture (Rave), carried out in a double-blind fashion. An unblinded pharmacist/designee was responsible for maintaining accountability, blinding, and dispensing the study drugs according to the handling instructions. All other study center personnel remained blinded to the study drug until database lock.""<br>""At Week 24, the 130 patients in the Tysabri group will be re-randomized (through a re- randomization step). Out of these 130 patients, approximately 34 (to account for potential dropouts to reach an approximate minimum of 30) random patients will be randomized (switched) to PB006. After re-randomization, the patient groups will be: Tysabri group (n=up to 96); Tysabri switch to PB006 group (n=up to 34); and PB006 group (n=up to 130).""<br>Baseline characteristics were similar between treatment groups before rerandomization. Baseline characteristics after rerandomization were not reported.</p>","Low risk","<p>""Patients were randomized dynamically using Medidata Randomization and Trial Supply Management integrated with electronic data capture (Rave), carried out in a double-blind fashion. An unblinded pharmacist/designee was responsible for maintaining accountability, blinding, and dispensing the study drugs according to the handling instructions. All other study center personnel remained blinded to the study drug until database lock.""</p><p>Safety/modified ITT population analysis.</p>","Some concerns","<p>The study did not report the proportion of missing outcome data separately for each treatment group, making it unclear whether missingness was balanced or could have introduced differential bias. The reported treatment discontinuation rates were similar across groups (10–11%), but this does not necessarily reflect missing outcome data for the analysis.</p><p>The trial states that ""for analysis of clinical endpoints using the FAS population, only available results will be used."" This suggests a complete-case analysis approach, which can introduce bias if missing data are not random.</p><p>No sensitivity analysis was conducted to assess the impact of missing data on the results, increasing uncertainty regarding potential bias.</p>","Low risk","<p>""Patients were randomized dynamically using Medidata Randomization and Trial Supply Management integrated with electronic data capture (Rave), carried out in a double-blind fashion. An unblinded pharmacist/designee was responsible for maintaining accountability, blinding, and dispensing the study drugs according to the handling instructions. All other study center personnel remained blinded to the study drug until database lock.""<br>Measurement of the outcome was the same between intervention groups.</p>","Some concerns","<p>Treatment-related AEs are preferred for reporting; however, only treatment-emergent AEs were reported.</p>","Some concerns","<p>Based on judgements of previous domains.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015123.pub2/full","10.1002/14651858.CD015123.pub2","1::overall","CD015123_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.628222290372192,-0.0701757363649636,-0.947589902862516,-0.308854677881867,-0.167504212998925,0.0271527402689978,TRUE,FALSE
3,1,"Number of participants who experienced at least one relapse","",NA,"SUBGROUP_AND_OVERALL","NCT01416181 (ASCEND)",2011,0,0.129477181493817,0,0,73,439,0,0,122,448,0,0.0167643405275827,100,0.610628,0.471566,0.790697,NA,"Low risk","<p>""Patients were randomly assigned by an interactive voice/web response system (IXRS, Bracket Global LLC, San Francisco, CA, USA).""<br>Clinical characteristics were balanced between treatment groups.</p>","Low risk","<p>""In part 1 of ASCEND, eligible patients were randomly assigned (1:1) to receive natalizumab or placebo of identical appearance. Patients were stratified by site and by EDSS score (3.0–5.5 vs 6.0–6.5). Patients and study staff were masked to treatment assignments in part 1.""<br>Appropriate analysis (ITT analysis) was used to estimate the effect of assignment to intervention.</p>","High risk","<p>The study did not report the proportion of missing outcome data separately for each treatment group, making it unclear whether missingness was balanced or could have introduced differential bias. The reported treatment discontinuation rates differ between groups (23% for placebo and 29% for natalizumab). These rates do not necessarily reflect the extent of missing outcome data used in the analysis.</p><p>The study reports using ITT analysis. However, the article does not provide details on how missing data were handled, and no sensitivity analysis was conducted to examine the impact of missing data on the results.</p><p>It is unclear whether treatment discontinuation is related to health.&nbsp;</p>","Low risk","<p>""In part 1 of ASCEND, eligible patients were randomly assigned (1:1) to receive natalizumab or placebo of identical appearance. Patients were stratified by site and by EDSS score (3.0–5.5 vs 6.0–6.5). Patients and study staff were masked to treatment assignments in part 1.""<br>Measurement of the outcome was the same between intervention groups.</p>","Low risk","<p>No selective reporting was identified.</p>","High risk","<p>Based on judgements of previous domains.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015123.pub2/full","10.1002/14651858.CD015123.pub2","1::overall","CD015123_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.628222290372192,-0.0701757363649636,-0.947589902862516,-0.308854677881867,-0.167504212998925,0.0271527402689978,TRUE,FALSE
4,1,"Number of participants who experienced at least one relapse","",NA,"SUBGROUP_AND_OVERALL","NCT01144052",NA,0,1.44734418671068,0,0,0,10,0,0,2,9,0,2.09480519480519,100,0.181818,0.009874,3.347951,NA,"","","","","","","","","","","","","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015123.pub2/full","10.1002/14651858.CD015123.pub2","1::overall","CD015123_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.628222290372192,-0.0701757363649636,-0.947589902862516,-0.308854677881867,-0.167504212998925,0.0271527402689978,TRUE,FALSE
